Dow Jones Top Company Headlines at 5 PM ET: FDA Reverses Course and Will Now Review Moderna's Flu Shot | Nvidia ...

Dow Jones
3 hours ago

FDA Reverses Course and Will Now Review Moderna's Flu Shot

The company's mRNA flu shot, if approved, could be available for the 2026-27 flu season.

----

Nvidia Wins Meta Deal. Its Gain Is Broadcom's Loss.

Nvidia stock has flatlined amid the competitive threat from Broadcom and other chip makers. But Meta Platforms is committing to purchases with the chip maker.

----

DoorDash Expects Ramped Up Spending to Dent First Quarter

The delivery giant expects adjusted EBITDA of $675 million to $775 million due to international investments and further investments in British company Deliveroo.

----

Molson Coors Profit, Sales Fall as Beer Demand Remains Soft

The maker of Blue Moon and Miller High Life said net sales fell 2.7%, to $2.66 billion, compared with analyst estimates of $2.72 billion.

----

Carvana Posts Higher Profit, Revenue on Record Car Sales

The used-car marketplace recorded revenue growing 58%, to $5.6 billion, up from $3.55 billion a year earlier.

----

EBay to Buy Depop From Etsy for $1.2 Billion

EBay Chief Executive Officer Jamie Ianonne said that the addition of Depop to its portfolio would boost its footprint across younger consumers.

----

Booking Sales, Profit Rise as More Travelers Make Reservations

The online travel agency said room nights increased 9% and gross bookings were up 16%.

----

Microsoft Says It Has Reached Its 100% Renewable Electricity Target

Tech giant uses renewable power purchase agreements to offset energy purchases, but critics say it is still burning fossil fuels from the grid.

----

Moody's Posts Higher Profit, Revenue

Moody's logged higher profit and revenue in the fourth quarter, as the company said efforts to scale new technologies across its business were paying off.

----

Glencore Earnings Fall Despite Record Metal Trading Performance

Glencore's metal traders booked record earnings last year amid optimal market conditions, while its energy-trading business suffered as the sector normalized.

----

Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory

The facility is part of the company's plans to invest $55 billion in U.S. manufacturing, research and development and technology through early 2029.

----

Bayer Shares Reverse Gains After Plan to Settle Roundup Litigation

Shares in the pharmaceutical and agriculture conglomerate fell as much as 10% in European morning trade, wiping out their gains from the previous session, when the stock shot up 7%.

----

MSG Sports Explores Separating Knicks, Rangers

CEO James Dolan said the move would provide each team with greater flexibility and create additional value for shareholders.

----

Jean Paul Gaultier Owner Puig Warns of Slowing Fragrance Market After Strong End to 2025

Madrid-listed shares rose as much as 6.6% after the owner of Jean Paul Gaultier and other brands wrapped up 2025 with climbing sales.

 

(END) Dow Jones Newswires

February 18, 2026 17:00 ET (22:00 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10